Reaching glycaemic targets while minimizing hypoglycaemia in insulin‐treated type 2 diabetes patients

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Diabetes, obesity and metabolism

• Publication date

  2008-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/j.1463-1326.2008.00841.xPMID 18577153
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A Critical Appraisal of the Role of Insulin Analogues in the Management of Diabetes Mellitus

  2012cited by this paper
• Comparison of Pharmacokinetics and Dynamics of the Long-Acting Insulin Analogs Glargine and Detemir at Steady State in Type 1 Diabetes: a Double-Blind, Randomized, Crossover Study

  2008cited by this paper
• Beyond insulin replacement: addressing the additional needs of the diabetes patient

  2008cited by this paper
• Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial.

  2008cited by this paper
• Initiate Insulin by Aggressive Titration and Education (INITIATE): A randomized study to compare initiation of insulin combination therapy in type 2 diabetic patients individually and in groups

  2008cited by this paper
• Towards peakless, reproducible and long‐acting insulins. An assessment of the basal analogues based on isoglycaemic clamp studies

  2007cited by this paper
• Negative binomial meta-regression analysis of combined glycosylated hemoglobin and hypoglycemia outcomes across eleven Phase III and IV studies of insulin glargine compared with neutral protamine Hagedorn insulin in type 1 and type 2 diabetes mellitus.

  2007cited by this paper
• Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes.

  2007cited by this paper
• Initiate Insulin by Aggressive Titration and Education (INITIATE)

  2007cited by this paper
• A 26-Week, Randomized, Parallel, Treat-to-Target Trial Comparing Insulin Detemir With NPH Insulin as Add-On Therapy to Oral Glucose-Lowering Drugs in Insulin-Naïve People With Type 2 Diabetes

  2007cited by this paper
• Insulin glargine versus NPH insulin therapy in Asian Type 2 diabetes patients.

  2007cited by this paper
• Comparison of Pharmacokinetics and Dynamics of the Long-Acting Insulin Analogs Glargine and Detemir at Steady State in Type 1 Diabetes

  2007cited by this paper
• Basal insulin or premix analogue therapy in type 2 diabetes patients.

  2007cited by this paper
• Exenatide Versus Insulin Glargine in Patients With Suboptimally Controlled Type 2 Diabetes: A Randomized TrialHeine RJ, for the GWAA Study Group (VU Univ, Amsterdam; et al) Ann Intern Med 143:559–569, 2005§

  2006cited by this paper
• Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study

  2006cited by this paper
• Contributions of fasting and postprandial glucose to hemoglobin A1c.

  2006cited by this paper
• Once-daily insulin glargine administration in the morning compared to bedtime in combination with morning glimepiride in patients with type 2 diabetes: an assessment of treatment flexibility.

  2006cited by this paper
• Fluctuation of Serum Basal Insulin Levels Following Single and Multiple Dosing of Insulin Glargine

  2006cited by this paper
• The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.

  2006cited by this paper
• Triple Therapy in Type 2 Diabetes: Insulin Glargine or Rosiglitazone Added to Combination Therapy of Sulfonylurea Plus Metformin in Insulin-Naïve Patients

  2006cited by this paper
• A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir.

  2005cited by this paper
• Lower within‐subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes

  2005cited by this paper
• Pharmacokinetic and glucodynamic variability: assessment of insulin glargine, NPH insulin and insulin ultralente in healthy volunteers using a euglycaemic clamp technique

  2005cited by this paper
• Exenatide versus Insulin Glargine in Patients with Suboptimally Controlled Type 2 Diabetes

  2005cited by this paper
• Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes.

  2005cited by this paper
• Initiating insulin therapy in type 2 Diabetes: a comparison of biphasic and basal insulin analogs.

  2005cited by this paper
• Reduced hypoglycemia risk with insulin glargine: a meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes.

  2005cited by this paper
• Growth in Type 1 diabetic children

  2004cited by this paper
• Insulin therapy for type 2 diabetes: rescue, augmentation, and replacement of beta-cell function.

  2004cited by this paper
• Insulin detemir and insulin aspart: a promising basal-bolus regimen for type 2 diabetes.

  2004cited by this paper
• The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients.

  2003cited by this paper
• A review of basal insulins

  2003cited by this paper
• Time-action profile of the long-acting insulin analogue insulin glargine in comparison to NPH insulin in Japanese volunteers.

  2003cited by this paper
• Timely addition of insulin to oral therapy for type 2 diabetes.

  2002cited by this paper
• Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin.

  2001cited by this paper
• Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group.

  2000cited by this paper
• Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

  2000cited by this paper
• Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo.

  2000cited by this paper
• Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro.

  2000cited by this paper
• Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.

  1998cited by this paper
• Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)

  1998cited by this paper
• Literature Reviews: Endocrinology

  1994cited by this paper
• The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.

  1993cited by this paper

• Titration of basal insulin or immediate addition of rapid acting insulin in patients not at target using basal insulin supported oral antidiabetic treatment - A prospective observational study in 2202 patients.

  2017cites this paper
• Antidiabetic treatment with gliptins: focus on cardiovascular effects and outcomes

  2015cites this paper
• Mechanism of the beneficial and protective effects of exenatide in diabetic rats.

  2014cites this paper
• Efficacy, usability and sequence of operations of a workflow‐integrated algorithm for basal–bolus insulin therapy in hospitalized type 2 diabetes patients

  2014cites this paper
• Beyond Glycemic Control in Diabetes Mellitus: Effects of Incretin-Based Therapies on Bone Metabolism

  2013cites this paper
• Choosing a Gliptin

  2011cites this paper
• Liraglutide in the treatment of type 2 diabetes mellitus: clinical utility and patient perspectives

  2010cites this paper
• Insulin glargine induced persistent intractable hypoglycemia, with variable presentations in older diabetic patients: an experience of 4 cases.

  2009cites this paper
• Early Insulin Treatment to Prevent Cardiovascular Disease in Prediabetes and Overt Diabetes

  2009cites this paper
• Optimum management of type 2 diabetes – timely introduction, optimization and intensification of basal insulin

  2008cites this paper